Financials in USD. Standardized financial statements.
A compact view of how Talis Biomedical Corporation turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue? | $412,000 | $3.65M | $0 | $10.94M | $3.98M | $2.39M |
| Revenue Growth? | -88.7% | 0.0% | -100.0% | +175.0% | +66.4% | 0.0% |
| Cost of Revenue? | $41,000 | $8.39M | $2.62M | $1.37M | $0 | $0 |
| Gross Profit? | $371,000 | -$4.74M | -$2.62M | $9.56M | $3.98M | $2.39M |
| Gross Margin? | +90.0% | -129.8% | 0.0% | +87.4% | +100.0% | +100.0% |
| Operating Expenses? | $67.19M | $110.40M | $197.39M | $100.75M | $26.70M | $21.43M |
| Operating Income? | -$66.81M | -$112.71M | -$200.01M | -$91.18M | -$26.70M | -$21.43M |
| EBITDA? | -$66.05M | -$101.41M | -$189.41M | -$89.76M | -$25.97M | -$20.78M |
| Income Before Tax | -$62.01M | -$113.01M | -$192.04M | -$91.13M | -$27.47M | -$21.34M |
| Income Tax Expense | $0 | $0 | -$1.58M | -$54,000 | -$42,000 | $93,000 |
| Net Income? | -$62.01M | -$113.01M | -$190.46M | -$91.08M | -$27.43M | -$21.34M |
| EPS? | $-34.12 | $-63.65 | $-126.13 | $-314.06 | $-182.88 | $-141.85 |
| Diluted EPS? | $-34.12 | $-63.65 | $-126.13 | $-314.06 | $-182.88 | $-141.85 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality